- Pfizer Inc (NYSE:PFE) announced that an interim futility analysis of the global Phase 3 trial, REALM-DCM of PF-07265803, indicated the trial is unlikely to meet its primary endpoint upon completion.
- Based on these results, the Phase 3 trial and further development of PF-07265803 will be discontinued. This decision is not based on safety concerns.
- Patients enrolled in the Phase 3 trial will stop study medication and complete any necessary follow-up evaluations. Detailed data from the REALM-DCM study will be presented at future medical meetings to help inform ongoing research.
- The asset was added when Pfizer acquired Array BioPharma for $11.4 billion in 2019, mainly focused on oncology but included a few non-cancer assets, including a Phase 3 drug being tested in a rare cardiovascular disease.
- Pfizer was testing PF-07265803, formerly ARRY-797, in patients with symptomatic dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA).
- LMNA-related DCM involves left ventricular enlargement and/or reduced systolic function. Arrhythmias and conduction system disease also sometimes accompany the rare inherited condition.
- Price Action: PFE shares are down 0.22% at $49.75 during the market session on the last check Thursday.
Cazoo Announces Conclusion Of Strategic Review Of Its EU Business
Cazoo proposes to wind down operations in mainland Europe to focus on core UK market
EU withdrawal ensures business has a plan that removes requirement for further funding
UK used car market largest in Europe with
